PERFORMANCE DATA SHEET 2209 Human CD86(p2)-muIg Fusion Protein*



For maximal recovery of contents please quick spin vial before opening

CATALOG#: 579-820 (Preservative-free) QUANTITY: 25 µg

CONCENTRATION: 0.5 mg/ml

Molecular Structure: Molecular Structure: A soluble fusion protein consisting of the extracellular (224 aa) domain of human CD86 fused to murine IgG2a Fc region. This molecules contains 1 *amino acid polymorphism* when compared to Genebank sequence HUMB72A: v(162)i, This residue has not been implicated in the *CD86-CD152 binding site(5)*. CD86 EC (224 aa):

(1)aplkiqayfnetadlpcqfansqnqslselvvfwqdqenlvlnevylgkekfdsvhskymgrtsfdsdswtlrlhnlqikdkglyqcii(90)rhkkptg(97)virihqmnselsvlanfsqpeivpisnitenvyi nltcssihgypepkkmsvllrtknstieydgv(162)mqksqdnvtelydvsislsvsfpdvtsnmtifciletdktrllsspfsieledpqpppdhip +linker (2 aa): gt

Murine IgG2a Fc +Hinge (233 aa):

eprgptikpcppckcpapnllggpsvfifppkikdvlmislspivtcvvvdvseddpdvqiswfvnnvevhtaqtqthredynstlrvvsalpiqhqdwmsgkefkckvnnkdlpapiertiskpkgsvrapqvyvlpppeeemtkkqvtltcmvtdfmpediyvewtnngktelnykntepvldsdgsyfmysklrvekknwvernsyscsvvheglhnhhttksfsrtpg

Predicted monomeric molecular weight: 52.2 kd. The molecule is dimeric and runs at about 115 kd in SDS-PAGE under native conditions. *Transfectant Cell Line:* CHO

INFORMATION: Human CD86 (B7-2) is a costimulating ligand for CD28 and CTLA-4. CD86 is expressed on activated B cells and blood monocytes(3).


References: **1.** C. Caux, et al, (1994) J Exp Med **180**: 1841-1847. **2.** C.B. Thompson, (1995) Cell **81**: 979-982. **3.** Leukocyte Typing V (S.F. Schlossman, et al, eds.) Oxford University Press, Oxford, (1995) p. 703-705. **4.** D. Mauri, et al, (1995) J Immunol **155**: 118-127.

STORAGE CONDITIONS: Store at 2 - 5ºC. Open under aseptic conditions. Freeze/Thawing is not recommended.

PRODUCT STABILITY: Product should retain activity for at least 12 months after shipping date when stored as recommended. Ship Date:______

BUFFER: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl. Product was 0.1 µm filtered and vialed under aseptic conditions.

PRODUCTION: Recombinant protein from (low FBS containing) tissue culture supernatant of transfectants was purified using affinity and size exclusion chromatography.



PERFORMANCE: CD86(P2)-muIg was reactive in an Enzyme Immuno Assay utilizing a Goat anti-Mouse Ig coated plate for capture and either CD152-muIg/Biotin recombinant protein (Catalog #501-030) or anti-CD86/Biotin (Catalog # 307-030) followed by Streptavidin/HRP and TMB/H₂O₂ substrate chromagen for detection.

CD86(p2)-muIg bound in FACS to cell surface CD28 present on cultured human T cell leukemic line HPB-MLT. Five x 10^5 cells per tube were washed and incubated 45 minutes on ice with 80 µl of CD86(P2)-muIg at **10 µg/ml**. Cells were washed twice and incubated with 2^0 reagent Goat anti-Mouse IgG/FITC (Catalog #232-011), after which they were washed three times, fixed and analyzed by FACS. Cells stained positive with a mean shift of **0.52** log₁₀ fluorescent units when compared to a recombinant muIg Fc negative control (Catalog #581-010) at a similar concentration.

*For Research use only. Not for use in Diagnostic Procedures.

Ancell Corporation P.O. Box 87 Bayport, MN 55003-0087 USA Phone: Toll free 800-374-9523 or 651-439-0835 Fax: 651-439-1940

Binding of CD86(P2)-muIg +GAM/FITC to human HPB-MLT cells